Bristol-Myers Squibb Company (BMY) key performance indicators and operating metrics (32 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Total Revenues, net | 11.5B | FY2026-Q1 |
| International revenues | 3.7B | FY2026-Q1 |
| Growth Portfolio Revenues | 6.2B | FY2026-Q1 |
| Legacy Portfolio Revenues | 5.3B | FY2026-Q1 |
| United States revenues | 7.8B | FY2026-Q1 |
| Amortization of acquired intangible assets | 437M | FY2026-Q1 |
| Licensing income | 13M | FY2026-Q1 |
| Acquired in-process research and development charges | 94M | FY2026-Q1 |
| Selling, general and administrative expenses | 1.6B | FY2026-Q1 |
| Effective tax rate, generally accepted accounting principles | 17.30 percent | FY2026-Q1 |
| Research and Development Expenses, Generally Accepted Accounting Principles | 2.6B | FY2026-Q1 |
| Earnings Per Share, Non-GAAP | 1.26 USD_per_share | FY2025-Q4 |
| Total Cash | 11.1B | FY2025-Q4 |
| Cash flow from operations | 2B | FY2025-Q4 |
Back to BMY overview · BMY earnings · BMY holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.